ADDED
As of February 20, 2026, there were 152,219,250 of the registrant s common stock outstanding and 2,760,000 of the registrant s Series A mandatory convertible preferred stock outstanding.
Business Segments We have four reportable segments, Bruker Scientific Instruments ( BSI ) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO, and Bruker Energy Supercon Technologies ( BEST ), which each comprise several divisions as disclosed below.
It offers comprehensive software solutions for workflow integration, automation, and artificial intelligence readiness, adhering to Findability, Accessibility, Interoperability, and Reusability ( FAIR ) data principles.
During 2025, we continued our focus on enhancing customer relationships and driving innovation with our key initiatives, which include expanding into high-potential markets, leveraging core strengths, and driving recurring revenue through aftermarket and connected services.
Furthermore, during 2025, we completed certain minority investments which align with the segment s goals of expanding its technological capabilities, entering new markets, and enhancing its product portfolio.
BSI BioSpin Segment s instruments are based on the following technology platforms: Instrument Name Description Market/Uses NMR Nuclear magnetic resonance Qualitative quantitative analytical technique to determine molecular structure purity of sample.
Molecules placed in a magnetic field, give off radio frequency signature recorded by a detector.
Used in Academia by pharmaceutical, biotechnology, food and beverage clinical companies, and other industrial users in life science and material science research.
This technique detects unpaired electrons unambiguously, whereas other techniques only provide indirect evidence of presence.
This technique can identify the paramagnetic species detected, presenting information on molecular structure giving insight into dynamic processes such as molecular motions or fluidity.
REMOVED
Our principal executive offices are located at 40 Manning Road, Billerica, MA 01821, and our telephone number is (978) 663-3660.
Business Segments We have four reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO, and Bruker Energy Supercon Technologies (BEST).
Furthermore, BSI BioSpin s product enables the characterization of mixtures and also complex materials, rendering them high value-added tools for a variety of industrial applications.
It offers comprehensive software solutions for workflow integration, automation, and artificial intelligence readiness, adhering to Findability, Accessibility, Interoperability, and Reusability (FAIR) data principles.
Automation: Provides solutions for lab automation and digitalization in Research Development and Quality Control.
3 During 2024, we continued our focus on accelerating growth, enhancing customer relationships, and driving innovation with our key initiatives, which include expanding into high-potential markets, leveraging core strengths, and driving recurring revenue through aftermarket and connected services.
Furthermore, during 2024, we completed our acquisition of Spectral Instruments Imaging and Chemspeed Technologies AG, and the minority investment in NovAliX, which align with the segment's goals of expanding its technological capabilities, entering new markets, and enhancing its product portfolio.
The acquisition of Spectral Instruments Imaging, a leader in preclinical in-vivo optical imaging systems, augments in the technology and product portfolio of the Bruker BioSpin Preclinical Imaging division, broadening its range of preclinical solutions for disease research.
Additionally, the acquisition of Chemspeed Technologies AG provides us entry into lab automation and digitalization, complementing our existing product platform of vendor-agnostic solutions.
Through the minority investment in NovAliX, we have taken a step into the preclinical Contract Research Organization (CRO) space, specializing in drug discovery services.